These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 32741482

  • 1. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA, Ioachimescu AG.
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of pituitary adenomas].
    Mezosi E, Nemes O.
    Orv Hetil; 2009 Sep 27; 150(39):1803-10. PubMed ID: 19758960
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A, Zgliczyński W, Komorowski J, Kos-Kudła B, Tabarin A, Kerlan V, Minuto FM, Scaroni C, Bolanowski M.
    Endokrynol Pol; 2019 Sep 27; 70(4):305-312. PubMed ID: 31274183
    [Abstract] [Full Text] [Related]

  • 4. Cabergoline in acromegaly.
    Kuhn E, Chanson P.
    Pituitary; 2017 Feb 27; 20(1):121-128. PubMed ID: 28025719
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr 27; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H, Shimatsu A, Okayama A, Sato T.
    Endocr J; 2020 Feb 28; 67(2):201-210. PubMed ID: 31723069
    [Abstract] [Full Text] [Related]

  • 9. Medical approach to pituitary tumors.
    Neggers SJ, van der Lely AJ.
    Handb Clin Neurol; 2014 Feb 28; 124():303-16. PubMed ID: 25248595
    [Abstract] [Full Text] [Related]

  • 10. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr 28; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 11. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy.
    Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, Coelho CE.
    Endocr Pract; 2007 Apr 28; 13(4):396-402. PubMed ID: 17669717
    [Abstract] [Full Text] [Related]

  • 12. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
    Cuny T, Barlier A, Feelders R, Weryha G, Hofland LJ, Ferone D, Gatto F.
    Ann Endocrinol (Paris); 2015 Feb 28; 76(1):43-58. PubMed ID: 25556152
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Multimodality treatment of pituitary adenomas.
    Oyesiku NM.
    Clin Neurosurg; 2005 Feb 28; 52():234-42. PubMed ID: 16626076
    [No Abstract] [Full Text] [Related]

  • 15. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
    Akirov A, Greenman Y, Glaser B, S'chigol I, Mansiterski Y, Eizenberg Y, Shraga-Slutzky I, Shimon I.
    Pituitary; 2018 Aug 28; 21(4):406-413. PubMed ID: 29728863
    [Abstract] [Full Text] [Related]

  • 16. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
    Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS.
    Front Endocrinol (Lausanne); 2021 Aug 28; 12():791633. PubMed ID: 35095761
    [Abstract] [Full Text] [Related]

  • 17. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
    Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, Ogura T, Date I, Hashimoto K, Makino H.
    J Endocrinol Invest; 2004 Dec 28; 27(11):1055-9. PubMed ID: 15754738
    [Abstract] [Full Text] [Related]

  • 18. The role of primary pharmacological therapy in acromegaly.
    Espinosa de los Monteros AL, Carrasco CA, Albarrán AA, Gadelha M, Abreu A, Mercado M.
    Pituitary; 2014 Jan 28; 17 Suppl 1(Suppl 1):S4-10. PubMed ID: 24166706
    [Abstract] [Full Text] [Related]

  • 19. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR, Romijn JA, Pereira AM, Roelfsema F.
    Expert Opin Pharmacother; 2005 Nov 28; 6(14):2393-405. PubMed ID: 16259571
    [Abstract] [Full Text] [Related]

  • 20. Evidence for dopamine agonists in the treatment of acromegaly.
    Jaquet P.
    J Endocrinol; 1997 Oct 28; 155 Suppl 1():S59-60. PubMed ID: 9389998
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.